PL377730A1 - Chromenonoindole - Google Patents

Chromenonoindole

Info

Publication number
PL377730A1
PL377730A1 PL377730A PL37773004A PL377730A1 PL 377730 A1 PL377730 A1 PL 377730A1 PL 377730 A PL377730 A PL 377730A PL 37773004 A PL37773004 A PL 37773004A PL 377730 A1 PL377730 A1 PL 377730A1
Authority
PL
Poland
Prior art keywords
chromenone
indoles
chromenone indoles
Prior art date
Application number
PL377730A
Other languages
English (en)
Polish (pl)
Inventor
Kai Schiemann
Henning Böttcher
Timo Heinrich
Günter Hölzemann
Amsterdam Christoph Van
Gerd Bartoszyk
Joachim Leibrock
Christoph Seyfried
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL377730A1 publication Critical patent/PL377730A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PL377730A 2003-04-04 2004-03-08 Chromenonoindole PL377730A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10315285A DE10315285A1 (de) 2003-04-04 2003-04-04 Chromenonindole

Publications (1)

Publication Number Publication Date
PL377730A1 true PL377730A1 (pl) 2006-02-06

Family

ID=32981019

Family Applications (2)

Application Number Title Priority Date Filing Date
PL377730A PL377730A1 (pl) 2003-04-04 2004-03-08 Chromenonoindole
PL04718300T PL1611126T3 (pl) 2003-04-04 2004-03-08 Chromenonoindole

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04718300T PL1611126T3 (pl) 2003-04-04 2004-03-08 Chromenonoindole

Country Status (18)

Country Link
US (1) US7968551B2 (enExample)
EP (1) EP1611126B1 (enExample)
JP (1) JP4740114B2 (enExample)
KR (1) KR20050119673A (enExample)
CN (1) CN1768056A (enExample)
AR (1) AR043834A1 (enExample)
AT (1) ATE446959T1 (enExample)
AU (1) AU2004226279B2 (enExample)
BR (1) BRPI0408467A (enExample)
CA (1) CA2520892C (enExample)
DE (2) DE10315285A1 (enExample)
DK (1) DK1611126T3 (enExample)
ES (1) ES2335665T3 (enExample)
MX (1) MXPA05010483A (enExample)
PL (2) PL377730A1 (enExample)
PT (1) PT1611126E (enExample)
WO (1) WO2004087692A1 (enExample)
ZA (1) ZA200508922B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
CN104045608B (zh) * 2013-03-11 2016-06-01 天津药物研究院有限公司 一种取代哌嗪化合物及制备维拉佐酮中间体的方法
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
US10316025B2 (en) 2015-06-03 2019-06-11 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE19730989A1 (de) 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate

Also Published As

Publication number Publication date
DK1611126T3 (da) 2010-01-18
CA2520892C (en) 2012-08-21
EP1611126A1 (de) 2006-01-04
JP4740114B2 (ja) 2011-08-03
WO2004087692A1 (de) 2004-10-14
ATE446959T1 (de) 2009-11-15
US7968551B2 (en) 2011-06-28
AU2004226279B2 (en) 2010-10-28
PT1611126E (pt) 2010-01-29
BRPI0408467A (pt) 2006-04-04
KR20050119673A (ko) 2005-12-21
CN1768056A (zh) 2006-05-03
MXPA05010483A (es) 2005-11-16
ZA200508922B (en) 2007-02-28
JP2006522034A (ja) 2006-09-28
DE10315285A1 (de) 2004-10-14
EP1611126B1 (de) 2009-10-28
CA2520892A1 (en) 2004-10-14
ES2335665T3 (es) 2010-03-31
PL1611126T3 (pl) 2010-02-26
AR043834A1 (es) 2005-08-17
DE502004010296D1 (de) 2009-12-10
US20060258680A1 (en) 2006-11-16
AU2004226279A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
TWI372050B (en) (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
PL375111A1 (en) Novel substituted indoles
SI1594840T1 (sl) Derivati piperidin-benzensulfonamida
ZA200603879B (en) Substituted indazole-O-glucosides
IL175490A0 (en) Substituted indazole-o-glucosides
GB0317665D0 (en) Qinazoline derivatives
EP1680131A4 (en) SUBSTITUTED INDOLE-O-GLUCOSIDES
GB0304515D0 (en) Standard
SI1682493T1 (sl) Amidoacetonitrilni derivati
ZA200603880B (en) Substituted indole-O-glucosides
PL1606277T3 (pl) Pochodne imidazol-4-iloetynylo-pirydyny
IL176562A0 (en) Amidopyrazole derivative
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
ZA200508922B (en) Chromenone indoles
PL1706373T3 (pl) Pochodne amidoacetonitrylu
ZA200600430B (en) Substituted spirobenzazepines
IL174187A0 (en) Carbamoyl-type benzofuran derivatives
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB2405272B (en) Lamp
GB0319793D0 (en) Pyridinylmorpholine derivatives
AU2003280821A8 (en) Beauveriolide derivative
GB0320548D0 (en) Supports
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
AU154939S (en) Spotlight
GB0327272D0 (en) Big match

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)